Arbutus Biopharma Corp Stock Investor Sentiment
| ABUS Stock | USD 2.73 0.01 0.37% |
Slightly above 54% of Arbutus Biopharma's investor base is interested to short. The analysis of the overall investor sentiment regarding Arbutus Biopharma Corp suggests that many traders are impartial. Arbutus Biopharma's investor sentiment overview provides quick insight into current market opportunities from investing in Arbutus Biopharma Corp. The current market sentiment, together with Arbutus Biopharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Arbutus Biopharma Corp stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Arbutus Biopharma stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Arbutus daily returns and investor perception about the current price of Arbutus Biopharma Corp as well as its diversification or hedging effects on your existing portfolios.
Arbutus |
Far too much social signal, news, headlines, and media speculation about Arbutus Biopharma that are available to investors today. That information is available publicly through Arbutus media outlets and privately through word of mouth or via Arbutus internal channels. However, regardless of the origin, that massive amount of Arbutus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Arbutus Biopharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Arbutus Biopharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Arbutus Biopharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Arbutus Biopharma alpha.
Arbutus Biopharma Performance against NYSE Composite
Price Growth (%) |
| Timeline |
1 | Contrasting Travere Therapeutics and Assembly Biosciences | 02/08/2024 |
2 | HC Wainwright Lowers Arbutus Biopharma Price Target to 5.00 | 03/05/2024 |
3 | Arbutus to Participate in Two Upcoming Investor Conferences | 03/08/2024 |
4 | Is Arbutus Biopharma In A Good Position To Deliver On Growth Plans | 04/01/2024 |
5 | iSono Health Applauded by Frost Sullivan for Ensuring Patient Comfort and Safety and Providing Quality Imaging and Diagnosis with its iSono Health ATUSA | 04/03/2024 |
6 | Moderna Shares Slip Over Covid Vaccine Patent Dispute, But Chart Signals Potential Rebound Ahead | 04/04/2024 |
7 | Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update | 04/18/2024 |
8 | Acquisition by Hastings David C of 316000 shares of Arbutus Biopharma at 2.9 subject to Rule 16b-3 | 04/19/2024 |
9 | Moderna Investors Should Beware Patent-Dispute Fallout - Seeking Alpha | 04/23/2024 |
Check out Arbutus Biopharma Hype Analysis, Arbutus Biopharma Correlation and Arbutus Biopharma Performance. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Complementary Tools for Arbutus Stock analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
Is Arbutus Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arbutus Biopharma. If investors know Arbutus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arbutus Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.44) | Revenue Per Share 0.109 | Quarterly Revenue Growth (0.66) | Return On Assets (0.29) | Return On Equity (0.60) |
The market value of Arbutus Biopharma Corp is measured differently than its book value, which is the value of Arbutus that is recorded on the company's balance sheet. Investors also form their own opinion of Arbutus Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Arbutus Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arbutus Biopharma's market value can be influenced by many factors that don't directly affect Arbutus Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arbutus Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Arbutus Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arbutus Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.